Shots:

• Under the terms of the agreement, Synaffix is eligible for up to $2B including spanning signature, program nomination & milestones along with tiered royalties
• Amgen receives exclusive, worldwide rights to develop & commercialize Ab-drug conjugates by using its Ab conjugation technology platforms incl. GlycoConnect, HydraSpace & select toxSYN linker payloads for one ADC program against cancer
• Additionally, Amgen holds an exclusive option to license for additional four programs & will be responsible for the R&D, manufacturing, & commercialization of the ADCs

Ref: PRNewswire | Image: Amgen

Related News:- Merck Signs a Research Collaboration and Commercial License Agreement with Mersana for Novel Antibody-Drug Conjugates